Methergín

Methylergometrine, the active ingredient in Methergín, is an ergot alkaloid presented as a sterile injectable solution for intramuscular, intravenous, or subcutaneous use. It is employed to prevent and treat postpartum hemorrhage and to manage uterine atony in obstetric patients.

GNH USA supplies Methergín as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Methergín is used in obstetrics to address conditions that involve uterine muscle tone and bleeding.

- Postpartum hemorrhage: helps control excessive bleeding after delivery. - Uterine atony: stimulates uterine contraction when the uterus fails to contract spontaneously. - Induction of labor (in some protocols): promotes cervical ripening and uterine activity to initiate labor.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Hypertension: transient increase in blood pressure. - Headache: pressure or throbbing sensation. - Flushing: redness of the skin, especially face.

Serious or Rare Side Effects: - Severe hypertension: marked elevation of blood pressure requiring medical attention. - Coronary spasm: chest pain due to reduced coronary blood flow. - Pulmonary edema: fluid accumulation in the lungs. - Allergic reaction: rash, itching, swelling, or anaphylaxis.

Careful assessment and monitoring are required when using Methergín.

- Cardiovascular assessment: evaluate blood pressure and heart status before administration. - Monitor blood pressure: observe for hypertension during and after dosing. - Caution in hypertension: avoid or use reduced dose in patients with pre‑existing high blood pressure. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Obstetric supervision: administer only under qualified obstetric care. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methylergometrine may interact with several drug classes.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension. - Other ergot derivatives: additive vasoconstrictive effects. - Strong CYP3A4 inhibitors: increased plasma concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible reduction in efficacy. - Calcium channel blockers: may enhance vasoconstriction.